Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Sage Therapeutics to Present at Upcoming August Investor Conferences
06:30am, Monday, 01'st Aug 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
06:30am, Tuesday, 19'th Jul 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that
Why Shares of Sage Therapeutics Climbed 15.6% This Week
10:20pm, Friday, 03'rd Jun 2022 The Motley Fool
Investors can see the finish line for the company's second marketed therapy.
Why Shares of Sage Therapeutics Climbed 15.6% This Week
06:20pm, Friday, 03'rd Jun 2022
Investors can see the finish line for the company's second marketed therapy.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
07:20pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals
04:33pm, Thursday, 02'nd Jun 2022
Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.
Sage Therapeutics to Present at Upcoming June Investor Conferences
06:30am, Thursday, 02'nd Jun 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
06:39pm, Wednesday, 01'st Jun 2022 Zacks Investment Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
8 Analysts Have This to Say About Sage Therapeutics
03:26pm, Tuesday, 24'th May 2022 Benzinga
Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
7
0
0
Sage Group ‘s Elliott Wave Decline Only Getting Started
06:34am, Thursday, 19'th May 2022 Investing.com
1 Reason to Buy Biogen Now, and 1 Reason to Wait
10:00am, Thursday, 05'th May 2022 The Motley Fool
The company just announced some big changes.
Analyst Ratings for Sage Therapeutics
04:15pm, Wednesday, 04'th May 2022 Benzinga
Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
06:30am, Wednesday, 04'th May 2022
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig
02:55pm, Tuesday, 03'rd May 2022 Zacks Investment Research
Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.
Sage Therapeutics, Inc. (SAGE) CEO Barry Greene on Q1 2022 Results - Earnings Call Transcript
01:54pm, Tuesday, 03'rd May 2022
Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2022 Earnings Conference Call May 3, 2022 8:00 AM ET Company Participants Helen Rubinstein - Investor Relations Barry Greene - Chief Executive Officer Jim Doh
